CY1110417T1 - Παραγωγα τρυπταμινης και αναλογες ενωσεις και φαρμακευτικες φαρμακοτεχνικες μορφες που περιεχουν αυτα - Google Patents

Παραγωγα τρυπταμινης και αναλογες ενωσεις και φαρμακευτικες φαρμακοτεχνικες μορφες που περιεχουν αυτα

Info

Publication number
CY1110417T1
CY1110417T1 CY20081101480T CY081101480T CY1110417T1 CY 1110417 T1 CY1110417 T1 CY 1110417T1 CY 20081101480 T CY20081101480 T CY 20081101480T CY 081101480 T CY081101480 T CY 081101480T CY 1110417 T1 CY1110417 T1 CY 1110417T1
Authority
CY
Cyprus
Prior art keywords
disorders
compounds
related compounds
pharmaceutical forms
forms containing
Prior art date
Application number
CY20081101480T
Other languages
Greek (el)
English (en)
Inventor
Nava Zisapel
Moshe Laudon
Original Assignee
Neurim Pharmaceuticals (1991) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharmaceuticals (1991) Limited filed Critical Neurim Pharmaceuticals (1991) Limited
Publication of CY1110417T1 publication Critical patent/CY1110417T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20081101480T 2000-10-03 2008-12-22 Παραγωγα τρυπταμινης και αναλογες ενωσεις και φαρμακευτικες φαρμακοτεχνικες μορφες που περιεχουν αυτα CY1110417T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL138825A IL138825A (en) 2000-10-03 2000-10-03 Pharmaceutical preparations containing tryptamine derivatives and similar compounds, and such new compounds
EP01974651A EP1331935B1 (en) 2000-10-03 2001-09-25 Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them

Publications (1)

Publication Number Publication Date
CY1110417T1 true CY1110417T1 (el) 2015-04-29

Family

ID=11074694

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101480T CY1110417T1 (el) 2000-10-03 2008-12-22 Παραγωγα τρυπταμινης και αναλογες ενωσεις και φαρμακευτικες φαρμακοτεχνικες μορφες που περιεχουν αυτα

Country Status (39)

Country Link
US (2) US6780884B2 (enExample)
EP (1) EP1331935B1 (enExample)
JP (1) JP2004533986A (enExample)
KR (1) KR100855385B1 (enExample)
CN (1) CN100518735C (enExample)
AR (1) AR035587A1 (enExample)
AT (1) ATE409474T1 (enExample)
AU (1) AU9416201A (enExample)
BG (1) BG107759A (enExample)
BR (1) BR0114464A (enExample)
CA (1) CA2423628C (enExample)
CL (1) CL2001002303A1 (enExample)
CR (1) CR6968A (enExample)
CY (1) CY1110417T1 (enExample)
CZ (1) CZ301098B6 (enExample)
DE (1) DE60136003D1 (enExample)
DK (1) DK1331935T3 (enExample)
EA (1) EA005918B1 (enExample)
EE (1) EE05192B1 (enExample)
ES (1) ES2315307T3 (enExample)
GT (1) GT200100197A (enExample)
HN (1) HN2001000218A (enExample)
HU (1) HU227163B1 (enExample)
IL (1) IL138825A (enExample)
IS (1) IS2607B (enExample)
MX (1) MXPA03002612A (enExample)
NO (1) NO20031396L (enExample)
NZ (1) NZ525587A (enExample)
PA (1) PA8529801A1 (enExample)
PE (1) PE20020411A1 (enExample)
PL (1) PL365679A1 (enExample)
PT (1) PT1331935E (enExample)
SI (1) SI1331935T1 (enExample)
SK (1) SK4042003A3 (enExample)
TW (1) TWI270544B (enExample)
UA (1) UA75091C2 (enExample)
UY (1) UY26946A1 (enExample)
WO (1) WO2002028347A2 (enExample)
ZA (1) ZA200303113B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1694323A4 (en) * 2003-12-19 2009-05-13 Elixir Pharmaceuticals Inc METHOD FOR TREATING A DISEASE
MXPA06009377A (es) * 2004-02-20 2007-03-07 Lifescape Biosciences Inc Composiciones y metodos para regulacion del sueno.
AU2006257815A1 (en) * 2005-06-10 2006-12-21 Bipar Sciences, Inc. PARP modulators and treatment of cancer
US7622495B2 (en) * 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
KR101760139B1 (ko) 2007-06-29 2017-07-31 클라렌슈 피티와이 리미티드 안투여를 통한 신경 또는 신경정신 장애의 치료 또는 예방용 약학 조성물
HRP20151367T1 (hr) * 2008-05-13 2016-01-29 Yale University Kimerne male molekule za pojaäśanje odgovora protutijela na stanice raka
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
CN103841890B (zh) 2011-05-31 2017-10-27 克拉伦苏股份有限公司 预防和治疗运动相关神经系统疾病的方法
US9073851B2 (en) 2011-10-28 2015-07-07 Board Of Regents, The University Of Texas System Compositions and methods for treating cancer
CN102816103B (zh) * 2012-08-20 2014-05-07 冉瑞琼 硫化天冬氨酸修饰的退黑素衍生物及其应用
TWI733772B (zh) * 2016-03-14 2021-07-21 美商身體邏輯股份有限公司 用於合成吲哚環核鹼基結合物之組成物及方法
CN116421600B (zh) * 2023-05-29 2024-08-23 重庆医科大学 色醇在制备治疗焦虑的药物中的应用
WO2025137730A1 (en) * 2023-12-22 2025-06-26 Alexander Shulgin Research Institute, Inc. N-substituted tryptamines and n-substituted lysergamides and their use as therapeutic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79264A0 (en) * 1986-06-27 1986-09-30 Univ Ramot Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
AUPO274596A0 (en) * 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
US6310085B1 (en) * 1997-10-03 2001-10-30 Clarencew Pty Ltd. Method for the treatment of neurological or neuropsychiatric disorders

Also Published As

Publication number Publication date
UY26946A1 (es) 2001-11-30
ZA200303113B (en) 2004-07-23
CN100518735C (zh) 2009-07-29
NO20031396D0 (no) 2003-03-27
GT200100197A (es) 2002-05-08
EA200300436A1 (ru) 2003-10-30
HU227163B1 (en) 2010-09-28
EE200300135A (et) 2003-08-15
JP2004533986A (ja) 2004-11-11
IS6752A (is) 2003-03-21
CZ301098B6 (cs) 2009-11-04
CA2423628C (en) 2011-04-26
PE20020411A1 (es) 2002-05-16
ES2315307T3 (es) 2009-04-01
US6780884B2 (en) 2004-08-24
HN2001000218A (es) 2002-05-09
KR100855385B1 (ko) 2008-09-04
CA2423628A1 (en) 2002-04-11
US20040029950A1 (en) 2004-02-12
EP1331935B1 (en) 2008-10-01
WO2002028347A2 (en) 2002-04-11
IL138825A0 (en) 2001-10-31
IS2607B (is) 2010-04-15
IL138825A (en) 2006-06-11
WO2002028347A3 (en) 2002-07-04
EP1331935A2 (en) 2003-08-06
NZ525587A (en) 2005-03-24
EE05192B1 (et) 2009-08-17
CZ2003940A3 (cs) 2003-10-15
EA005918B1 (ru) 2005-06-30
DK1331935T3 (da) 2009-02-02
AR035587A1 (es) 2004-06-16
MXPA03002612A (es) 2004-04-02
CN1582147A (zh) 2005-02-16
TWI270544B (en) 2007-01-11
BR0114464A (pt) 2004-01-20
PL365679A1 (en) 2005-01-10
ATE409474T1 (de) 2008-10-15
AU9416201A (en) 2002-04-15
CL2001002303A1 (es) 2010-06-25
SK4042003A3 (en) 2003-09-11
PA8529801A1 (es) 2002-12-30
SI1331935T1 (sl) 2009-04-30
CR6968A (es) 2004-02-25
HUP0302616A2 (hu) 2003-11-28
EP1331935A4 (en) 2004-12-01
KR20030051689A (ko) 2003-06-25
DE60136003D1 (de) 2008-11-13
US20050020664A1 (en) 2005-01-27
BG107759A (bg) 2004-01-30
PT1331935E (pt) 2009-01-19
UA75091C2 (en) 2006-03-15
NO20031396L (no) 2003-03-27
HK1074163A1 (zh) 2005-11-04

Similar Documents

Publication Publication Date Title
FI941022A0 (fi) Spirosykliset piperidiinijohdannaiset
ATE316076T1 (de) Benzimidazol-derivate und diese enthaltende pharmazeutische zusammensetzungen
UA27238C2 (uk) Індолінові похідні, а також їх фармацевтично прийнятні солі, що є антагоністами вазопресинових v1-рецепторів, спосіб їх одержання, проміжні продукти і фармацевтична композиція
DK0591333T3 (da) Azanorbornanderivater
CY1114919T1 (el) Anti-mag ανθρωποποιημενα αντισωματα και οι χρησεις τους για την αντιμετωπιση του εγκεφαλικου επεισοδιου
CY1109104T1 (el) 1,2,3,4 τετρα-υποκατεστημενη ινδολη για την αντιμετωπιση ασθενειων του αναπνευστικου
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
SE0201635D0 (sv) Novel compounds
SE0203713D0 (sv) Novel compounds
AR007118A1 (es) 4(3h)-quinazolinonas 2,3 disustituidas y composiciones farmaceuticas que las contienen
DK0641328T3 (da) Broforbundne, azabicykliske derivater som substans P-antagonister
AR002705A1 (es) Un nuevo compuesto de indolina, un proceso para su preparacion y composiciones farmaceuticas que lo contienen.
DK0675886T3 (da) Aminomethylensubstituerede ikke-aromatiske heterocykler og deres anvendelse som substance P-antagonister
CY1106645T1 (el) Παραγωγα 1,2,4 τριαμινοβενζολης χρησιμα για τη θεραπευτικη αντιμετωπιση διαταραχων του κεντρικου νευρικου συστηματος
NO20050122L (no) Prodrug av eksitasjonsaminosyrer
MXPA03002612A (es) Derivados de triptamina y compuestos analogos, asi como formulaciones farmaceuticas que los contienen.
AR029461A1 (es) Derivados de 4-fenil-1-piperazinilo, - piperidinilo y -tetrahidropiridilo , composiciones farmaceuticas que los comprenden y el uso de los mismos para la fabricacion de un medicamento
DE60327709D1 (de) Fusionierte cycloalkyl amid- und carbonsäure-derivate und deren therapeutische verwendung zur behandlung von u.a. epilepsie
ATE398614T1 (de) Triazolverbindungen und ihre therapeutische verwendung
CY1106225T1 (el) Διαδικασια για την παρασκευη της 2-μεθυλ πιπepαζινης
MXPA05008236A (es) Derivados novedosos de 2,3-benzodiazepina substituidos.
EA200602081A1 (ru) Пиридиновые производные алкилоксиндолов в качестве агентов, активных в отношении рецептора 5-нт7
EA200501053A1 (ru) Производные 1,2,4-триаминобензола, пригодные для лечения расстройств центральной нервной системы